Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Abstract

Explosive growth of nanomedicines continues to significantly impact the therapeutic strategies for effective cancer treatment. Despite the significant progress in the development of advanced nanomedicines, successful clinical translation remains challenging. As cancer nanomedicine is a multidisciplinary field, the fundamental problem is that the knowledge gaps stem from different vantage points in the understanding of cancer nanomedicines. The complexities and heterogenecity of both nanomedicines and cancer are further demanding the integration of highly diverse expertise to develop clinically translatable cancer nanomedicines. This progress report aims to discuss the current understanding of cancer nanomedicines between different research areas in terms of nanoparticle engineering, formulation, tumor patho-physiology and clinical medicine, as well as to identify the knowledge gaps lying at the interface between the different fields of research in nanomedicine. Here we also highlight for the necessity to harmonize the multidisciplinary effort in the research of nanomedicines in order to bridge the knowledge and to advance the full understanding in cancer nanomedicines. A paradigm shift is needed in the strategic development of disease specific nanomedicines in order to foster the successful translation into clinic of future cancer nanomedicines.

Biocompatible DNA/5-Fluorouracil-Gemini Surfactant-Functionalized Gold Nanoparticles as Promising Vectors in Lung Cancer Therapy

“…However, advances in new therapies are essential to find ways to selectively act on fast-growing malignant cells that do not affect healthy cells [5]. Significant progress has been made in nanomedicine to facilitate drug delivery and improve its adsorption, directly acting on the site of damage and reducing multiple side effects in patients [6,7]. Furthermore, the possibility of the controlled manipulation of material at the nanometerlength scale, facile functionalization with different drugs, improved solubility, permeability, mational change in the new nanocomplexes was remarkable; that is, the Au@16-Ph-16 precursor specifically induced the reversible DNA-5-Fu compaction at the appropriate Au@16-Ph-16/DNA molar ratio.…”

Anti-Inflammatory Nanomedicines: What Does The Future Hold?

“…Notwithstanding the reported advantages provided by nanotechnology and the optimistic predictions about anti-inflammatory nanomedicines made by researchers on the basis of development of different generations of nanosystems by vascular permeability, overexpression of biomarkers, immunomodulation and macrophage repolarization [28], anti-inflammatory nanomedicines have not been yet fully established commercially. In this context, only certain areas such as cancer therapeutics have been increased in the clinical translation and commercialization [29].…”

Drug Transporters

“…In the last decade, several studies have found that NP surfaces have a major influence in the nanocarrier performance, because they are responsible for establishing contact with biological systems. In this regard, NP surface engineering plays a main role in DDS performance in vivo, including stability in biological milieu, and could help in overcoming the limitations of other DDS (Balasubramanian et al 2018).…”